SUPERNUS PHARMACEUTICALS, INC. Intangible Assets, Net (Excluding Goodwill)
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Intangible Assets, Net (Excluding Goodwill) of $469.46 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2026-08-03
- 2026-06-30: Intangible Assets, Net (Excluding Goodwill) $469.46M.
- 2026-03-31: Intangible Assets, Net (Excluding Goodwill) $549.71M.
- 2025-12-31: Intangible Assets, Net (Excluding Goodwill) $569.46M.
- 2025-09-30: Intangible Assets, Net (Excluding Goodwill) $623.48M.
| Period end | Intangible Assets, Net (Excluding Goodwill) | Intangible Assets, Net (Excluding Goodwill) as first filed |
|---|---|---|
| 2026-06-30 | $469.46M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $549.71M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $569.46M 10-Q · filed 2026-08-03 | |
| 2025-09-30 | $623.48M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $481.31M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $502.13M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $521.91M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $540.16M 10-Q · filed 2024-11-04 | |
| 2024-06-30 | $559.64M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $579.75M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $599.89M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $641.15M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $662.39M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $682.50M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $702.46M 10-Q · filed 2023-11-08 | |
| 2022-09-30 | $722.76M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $743.40M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $764.05M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $784.69M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $346.62M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $352.63M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $358.74M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $364.34M 10-K · filed 2022-04-13 | |
| 2020-09-30 | $402.26M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $408.27M 10-Q · filed 2020-08-17 | |
| 2020-03-31 | $23.58M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $24.84M 10-K · filed 2021-03-08 | |
| 2019-09-30 | $26.10M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $28.79M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $30.06M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $31.37M 10-K · filed 2020-02-28 | |
| 2018-09-30 | $32.57M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $33.79M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $34.86M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $36.02M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $37.16M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $28.99M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $29.45M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $36.35M 10-K · filed 2018-03-01 | $16.49M 10-K · filed 2017-03-16 |
| 2016-09-30 | $15.53M 10-Q · filed 2017-01-20 | |
| 2016-06-30 | $15.79M 10-Q/A · filed 2017-01-23 | |
| 2016-03-31 | $16.11M 10-Q/A · filed 2017-01-20 | |
| 2015-12-31 | $976.00K 10-K · filed 2017-03-16 | |
| 2015-09-30 | $16.63M 10-Q/A · filed 2017-01-20 | |
| 2015-06-30 | $110.00K 10-Q/A · filed 2017-01-23 | $11.60M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $167.00K 10-Q/A · filed 2017-01-20 | $7.84M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $5.43M 10-Q/A · filed 2017-01-20 | |
| 2014-09-30 | $4.13M 10-Q/A · filed 2017-01-20 | |
| 2014-06-30 | $3.08M 10-Q · filed 2014-08-12 | |
| 2014-03-31 | $2.16M 10-Q · filed 2014-05-13 | |
| 2013-12-31 | $1.16M 10-K · filed 2015-03-12 | |
| 2013-09-30 | $817.00K 10-Q · filed 2013-11-13 | |
| 2013-06-30 | $568.00K 10-Q · filed 2013-08-14 | |
| 2013-03-31 | $626.00K 10-Q · filed 2013-05-15 | |
| 2012-12-31 | $683.00K 10-K · filed 2014-03-21 | |
| 2012-09-30 | $740.00K 10-Q · filed 2012-11-02 | |
| 2012-06-30 | $798.00K 10-Q · filed 2012-08-13 | |
| 2012-03-31 | $855.00K 10-Q · filed 2012-06-08 | |
| 2011-12-31 | $912.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |